The english version of the website of the School of Medicine is under development


Inhaled Immunotherapy Administration for Lung Cancer; Efficient? Certainly Possible.

TitleInhaled Immunotherapy Administration for Lung Cancer; Efficient? Certainly Possible.
Publication TypeJournal Article
Year of Publication2018
AuthorsSapalidis, K., Zarogoulidis P., Huang H., Bai C., Wen Y., Wang L., Boniou K., Karapantzos I., Karapantzou C., Karanikas M., Thomaidis V., Kosmidis C., Sardeli C., Benhassen N., Man Y-G., Florou M. C., Mantalovas S., Laskou S., Giannakidis D., Koulouris C., Amaniti A., Kesisoglou I., & Hohenforst-Schmidt W.
JournalJ Cancer
Date Published2018

Lung cancer is still diagnosed at a late stage in most lung cancer patients. Regarding Non-small Cell lung cancer there are novel therapies such as; tyrosine kinase inhibitors and immunotherapy. Currently we have two immunotherapies that can be used either as first-line treatment or second line treatment; pembrolizumab and nivolumab. A third one is being investigated as a combination of immunotherapy; ipilimumab. Aerosol treatment has been investigated for many diseases not only for the lung, but also for systematic diseases. The design of cups was found the most significant factor in producing significant effects. The comparison of cups reveals the design J as the most capable of reducing the droplets at a minimum size of mass median aerodynamic diameter (MMAD) MMAD=1.99. Drug effect comes second in sequence (F=62.04) showing that nivolumab is the most drastic preparation at low particle sizes (1.89), two drugs share an intermediate particle diameter (pembrolizumab and ipilimumab). In total drugs demonstrate a decreasing droplet size: Ipilimumab>Pembrolizumab> Nivolumab.

Alternate JournalJ Cancer
PubMed ID29581792
PubMed Central IDPMC5868180


Secretariat of the School of Medicine


Schoole of Medicince presence in social networks
Follow Us or Connect with us.